Methylergonovine Maleate

Angina Pectoris, Variant, Postpartum uterine subinvolution, Vaginal Bleeding + 3 more
Treatment
7 Active Studies for Methylergonovine Maleate

What is Methylergonovine Maleate

MethylergometrineThe Generic name of this drug
Treatment SummaryMethylergonovine is a drug related to ergonovine, but with an extra carbon-hydrogen (CH2) group added.
Methergineis the brand name
Methylergonovine Maleate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Methergine
Methylergometrine
1946
32

Effectiveness

How Methylergonovine Maleate Affects PatientsMethylergometrine is a drug derived from ergonovine, used to prevent heavy bleeding after childbirth or an abortion. It works by affecting certain receptors in the body. This drug increases the activity of the uterus, and as the dose increases, the contractions become more forceful and longer-lasting, with a greater resting tone.
How Methylergonovine Maleate works in the bodyMethylergometrine helps the uterus contract more strongly, quickly, and with more force. This tightens the uterus and helps the third stage of labor progress faster, reducing blood loss. It does this by blocking dopamine receptors in the uterus and making the muscles contract more powerfully.

When to interrupt dosage

The endorsed measure of Methylergonovine Maleate is contingent upon the diagnosed disorder, including Uterine Atony, Vaginal Bleeding and Postpartum Haemorrhage (PPH). The measure of dosage differs, in accordance with the technique of delivery (e.g. Oral or Tablet, coated) documented in the table beneath.
Condition
Dosage
Administration
Postpartum Hemorrhage
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous
Spasm provocation test
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous
Angina Pectoris, Variant
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous
Postpartum uterine subinvolution
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous
Vaginal Bleeding
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous
Uterine Inertia
0.2 mg, , 0.2 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous

Warnings

Methylergonovine Maleate has two contraindications, and it should not be ingested while having any of the conditions enumerated in the table below.Methylergonovine Maleate Contraindications
Condition
Risk Level
Notes
Pre-eclampsia
Do Not Combine
Hypertensive disease
Do Not Combine
There are 20 known major drug interactions with Methylergonovine Maleate.
Common Methylergonovine Maleate Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
Methylergometrine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.
4-Methoxyamphetamine
Major
Methylergometrine may increase the hypertensive and vasoconstricting activities of 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
Major
Methylergometrine may increase the vasoconstricting activities of 5-methoxy-N,N-dimethyltryptamine.
Abediterol
Major
Methylergometrine may increase the hypertensive and vasoconstricting activities of Abediterol.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Methylergometrine.
Methylergonovine Maleate Toxicity & Overdose RiskSigns of taking too much of this drug may include high blood pressure, seizures, headaches, low blood pressure, nausea, and vomiting.

Methylergonovine Maleate Novel Uses: Which Conditions Have a Clinical Trial Featuring Methylergonovine Maleate?

8 active trials are currently underway to investigate the viability of Methylergonovine Maleate as a treatment for Uterine Atony, Postpartum Uterine Subinvolution and Variant Angina Pectoris.
Condition
Clinical Trials
Trial Phases
Postpartum uterine subinvolution
0 Actively Recruiting
Uterine Inertia
1 Actively Recruiting
Phase 2
Angina Pectoris, Variant
0 Actively Recruiting
Postpartum Hemorrhage
5 Actively Recruiting
Phase 2, Not Applicable
Spasm provocation test
0 Actively Recruiting
Vaginal Bleeding
1 Actively Recruiting
Not Applicable

Methylergonovine Maleate Reviews: What are patients saying about Methylergonovine Maleate?

5Patient Review
8/21/2019
Methylergonovine Maleate for Hemorrhage Following Delivery of Baby
I had a c-section and was in a lot of pain afterwards. The ER prescribed this to me and it really helped. I didn't have any bad cramping like they said I might, just some diarrhea. But by the time I finished the medication, I felt way better.
5Patient Review
8/24/2011
Methylergonovine Maleate for Hemorrhage Following Delivery of Baby
I was flooding heavily after giving birth to my son, and Methergine really helped slow down the flow within 24 hours. The bleeding stopped completely within one week, which was a huge relief.
3.7Patient Review
4/10/2019
Methylergonovine Maleate for Hemorrhage Following Delivery of Baby
This medication was prescribed to me post-partum. I took as directed, three pills per day for five days. It helped with the bleeding and most of the pain, but unfortunately caused some pretty intense headaches.
2.3Patient Review
8/29/2014
Methylergonovine Maleate for Hemorrhage Following Abortion
I began feeling dizzy about an hour after each pill, and by the end of the three-day course, I was also experiencing cramping in my upper legs. The jury is still out on whether or not this treatment was effective for me, as there hasn't been a change in my post-op bleeding.
2.3Patient Review
9/20/2012
Methylergonovine Maleate for Hemorrhage Following Delivery of Baby
Though this medication was successful in stemming the bleeding from my miscarrying, the leg cramps I experience 30 minutes afterwards are unbearable. I can barely walk or stand for hours at a time as a result.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about methylergonovine maleate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the adverse effect of methylergonovine?

"Among the most frequently reported adverse reactions are high blood pressure, seizures, and headaches. Other reactions include abdominal pain, nausea, and vomiting."

Answered by AI

When should Methergine not be given?

"Use of methylergonovine is not recommended for patients with high blood pressure. Injecting methylergonovine intravenously should not be done routinely because it could cause a sudden increase in blood pressure that could lead to a stroke."

Answered by AI

Is methylergonovine used for miscarriage?

"The medication Methergine®, which causes uterine contractions, is often used together with another medication, misoprostol, to treat heavy bleeding during early pregnancy loss. Methergine® begins working within 5-10 minutes, making it a good choice to use initially to manage early pregnancy loss hemorrhage."

Answered by AI

What is methylergonovine maleate used for?

"This medicine is used to prevent and control bleeding from the uterus that can happen after childbirth. It belongs to the class of medicines called ergot alkaloids. This medicine works by acting directly on the smooth muscles of the uterus and prevents bleeding after giving birth."

Answered by AI

Clinical Trials for Methylergonovine Maleate

Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

Educational Video for Uterine Fibroids

18 - 55
All Sexes
Philadelphia, PA
Uterine fibroids are a common condition that can cause heavy and/or painful menstrual bleeding. There are many treatment options, but they vary in efficacy, side effects, short-term recovery and long-term implications for future fertility. Patients can have difficulty deciding between these options. In this study, the investigators will randomly assign patients seeking treatment for fibroids to receive an educational video on fibroids and their treatment, versus usual care (no video). The investigators will assess their decisional conflict with and without exposure to the video using a validated survey to see if exposure to the educational video helps them make decisions.
Recruiting
Has No Placebo
Hospital of the University of PennsylvaniaAnuja Dokras, MD
Image of Vanderbilt University Medical Center in Nashville, United States.

Risk Prediction Model for Postpartum Hemorrhage

Any Age
Female
Nashville, TN
This research project aims to enhance the safety of childbirth by using advanced computer models to predict the risk of postpartum hemorrhage (PPH). PPH is a significant concern for mothers during and after delivery. Current risk assessment tools are basic and do not adapt to changing conditions. This study will investigate whether a new and recently validated model for predicting PPH, combined with a provider-facing Best Practice Advisory (BPA) regarding currently recommended strategies triggered by an increased predicted risk, can improve perinatal outcomes. This study will compare the current category based risk assessment tool with a new, enhanced prediction model which calculates risk based on 21 factors, automatically updates as new information becomes available during labor and, if elevated, provides a provider-facing Best Practice Advisory (BPA) recommending consideration of strategies that are institutionally agreed to represent high-quality practice. Investigators hypothesize that the enhanced care approach will result in improved perinatal outcomes. The goal of the study is to improve the wellbeing of mothers during childbirth by harnessing the power of modern technology and data analysis.
Recruiting
Has No Placebo
Vanderbilt University Medical CenterHolly Ende, MD
Have you considered Methylergonovine Maleate clinical trials? We made a collection of clinical trials featuring Methylergonovine Maleate, we think they might fit your search criteria.Go to Trials
Image of University of Chicago in Chicago, United States.

Deuterated Oxytocin for Postpartum Hemorrhage

18 - 50
Female
Chicago, IL
Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynamics of all plasma oxytocin to see how concentrations correspond to the contractile effect on the uterus. After delivery of the fetus, study subjects will receive a bolus of IV deuterated oxytocin followed by an unlabeled oxytocin infusion. Venous blood samples drawn at multiple time points (within 1 hour after delivery) will be analyzed for plasma concentrations of labeled and unlabeled (endogenous + exogenous infused) oxytocin over time. Plasma concentrations will be compared with 0-10 uterine tone scores measuring uterine contraction strength, to describe the concentration-effect relationship. The goal of this study is to define both the pharmacokinetics and pharmacodynamics of oxytocin in parturients to help identify the cause(s) of failed first-line oxytocin therapy.
Phase 2
Recruiting
University of Chicago (+1 Sites)Naida M Cole, MD
Image of George Washington University Hospital in Washington, United States.

Tranexamic Acid for Postpartum Hemorrhage

18 - 50
Female
Washington, United States
In part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15 mg/kg) in an escalating fashion by cohort with the lowest dose first. The drug was administered intravenously at the time of umbilical cord clamping for a non-emergent cesarean section. A maximum of 1 gram was administered. TXA serum levels at several time points after delivery were assayed to see if they reach the target plasma concentration of 10 microg/mL. A PK model was constructed for determining the optimal TXA dose administered at parturition. In part 2 of the study, the investigators aim to compare PKPD endpoints using prophylactic TXA via IV and IM routes administered pre-cord clamp. The investigators will administer 1000 mg TXA within 10 minutes of skin incision via intravenous infusion (up to n=15), intravenous bolus \< 2 minutes (up to n=15) and intramuscular injection (up to n=15). The investigators will target women undergoing scheduled cesarean delivery greater than 34 weeks gestation, women undergoing vaginal delivery \> 34 weeks of gestation and morbidly obese women (BMI\>=40) undergoing either a vaginal or cesarean delivery. The investigators will use advanced modeling techniques to determine time to achieve PKPD targets and duration remaining at those targets. The goal will be to determine how the optimal dose may vary if route of administration is modified. The investigators plan to enroll 45 patients in addition to the 43 that were enrolled during part 1. Our goal is to 30 participants, but the investigators will enroll 45 to account for lost to follow-up. The investigatorsalso aim to enroll 30 patients undergoing vaginal delivery and 30 morbidly obese women (BMI \> 50) undergoing either a vaginal or cesarean delivery but the investigators will enroll 45 patients for each of these groups to account for loss to follow up. In addition, the investigators will enroll 30 pregnant patients receiving no medication acting as the control group, but the investigators will enroll 45 to account for loss to follow up.
Phase 2
Recruiting
George Washington University Hospital (+4 Sites)Homa K Ahmadzia, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security